Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Clene Inc. CLNN

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Effect 1-for-20 Reverse Stock Split

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will effect a … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

Clene Inc. (NASDAQ: CLNN) Reveals Important Findings From HEALEY ALS Platform Trial

Clene (NASDAQ: CLNN), through its wholly owned subsidiary, Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). This … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

Clene Inc. (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently participated in the 72nd Emerging Growth Conference. EmergingGrowth.com is a … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced that management will present at … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for CNM-Au8(R) Compassionate Use

Clene (NASDAQ: CLNN) and its subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and multiple sclerosis (“MS”), recently announced significant updates to their ACT-EAP for … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

Clene Inc. (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024, Promoting CNM-Au8(R) Neuronal Health Therapy

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently participated in three investor conferences during May … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases

Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a … Continue reading

Posted in Clene Inc. CLNN | Leave a comment

Clene Inc. (NASDAQ: CLNN) Announces Key Operational Highlights as part of First Quarter 2024 Financial Results

Clene (NASDAQ: CLNN), a late-stage clinical biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), along with its wholly-owned subsidiary Clene Nanomedicine, Inc., recently announced its first quarter 2024 financial … Continue reading

Posted in Clene Inc. CLNN | Leave a comment